Your browser doesn't support javascript.
loading
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
Lopes Cardozo, Josephine M N; Andrulis, Irene L; Bojesen, Stig E; Dörk, Thilo; Eccles, Diana M; Fasching, Peter A; Hooning, Maartje J; Keeman, Renske; Nevanlinna, Heli; Rutgers, Emiel J T; Easton, Douglas F; Hall, Per; Pharoah, Paul D P; van 't Veer, Laura J; Schmidt, Marjanka K.
Afiliación
  • Lopes Cardozo JMN; Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Andrulis IL; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Bojesen SE; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Dörk T; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Eccles DM; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Fasching PA; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Hooning MJ; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Keeman R; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Nevanlinna H; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Rutgers EJT; Department of Gynecology and Obstetricss, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Easton DF; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Hall P; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Pharoah PDP; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • van 't Veer LJ; Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Schmidt MK; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
J Clin Oncol ; 41(10): 1849-1863, 2023 04 01.
Article en En | MEDLINE | ID: mdl-36689693
ABSTRACT

PURPOSE:

A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.

METHODS:

Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.

RESULTS:

The PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment) OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent.

CONCLUSION:

An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos